JB Chemicals & Pharmaceuticals Q4 Results: Profit, Revenue Meet Estimates
The international business revenue saw a growth of 9%, reaching Rs 430 crore.
JB Chemicals & Pharmaceuticals Ltd.'s consolidated net profit jumped 16% in the fourth quarter of the financial year 2025, meeting analysts' estimates.
The company posted a profit of Rs 146 crore as compared to Rs 126 crore in the year-ago period, according to an exchange filing on Wednesday. Analysts tracked by Bloomberg had estimated a net profit of Rs 142 crore.
JB Chemicals Q4 Highlights (Consolidated, YoY)
Revenue up 10% to Rs 949 crore versus Rs 862 crore (Bloomberg estimate: Rs 939 crore).
Ebitda up 14% to Rs 226 crore versus Rs 198 crore (Bloomberg estimate: Rs 227 crore).
Margin expands to 23.8% versus 23% (Bloomberg estimate: 24.2%).
Net profit up 16% to Rs 146 crore versus Rs 126 crore (Bloomberg estimate: Rs 142 crore).
The revenue growth was supported by robust performance in the domestic formulations business and a strong rebound in the contract development and manufacturing organisation business during the fourth quarter.
The domestic business revenue experienced an 11% increase, reaching Rs 519 crore. Both the chronic and acute product portfolios within the domestic business performed well during the quarter.
The international business revenue saw a growth of 9%, reaching Rs 430 crore. Within the international business, the CDMO business, the Russian market, and the rest-of-the-world regions recorded good growth during the quarter.
Shares of JB Chemicals closed 1.94% higher at Rs 1,610.5 apiece on the BSE, compared to a 0.22% advance in the benchmark Sensex.
